

truncated RANTES polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-2 and has chemokine antagonistic activity.

28. (New) An isolated amino-terminally truncated RANTES comprising residues 4-68 of a RANTES polypeptide according to RANTES (SEQ ID NO: 2), wherein the truncated RANTES polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-3 and has chemokine antagonistic activity.
29. (New) An isolated amino-terminally truncated RANTES comprising residues 5-68 of an RANTES polypeptide according to SEQ ID NO: 2, wherein the truncated RANTES polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-4 and has chemokine antagonistic activity.
30. (New) The isolated amino-terminally truncated RANTES of claims <sup>27-28</sup>~~26-29~~, wherein the truncated RANTES polypeptide is in glycosylated form.
31. (New) A pharmaceutical composition comprising an isolated truncated RANTES polypeptide according to any one of claims <sup>27-28</sup>~~25-29~~, wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
32. (New) The pharmaceutical composition according to claim 31, wherein the isolated truncated RANTES polypeptide is in glycosylated form.

## **RESPONSE**

### **Pending claims**